IP Library Granted Patent US 7,598,382
Granted Patent B2
US 7,598,382 · App. 11/275,553 · Granted Oct 6, 2009

Aryl substituted imidazoquinolines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,598,382
App. No.
11/275,553
Granted
Oct 6, 2009
Kind
B2
Abstract

Aryl substituted imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.

Claims (36)

1. A compound of formula (III):

wherein:

R 2 is selected from the group consisting of:

—R 4 ,

—X—R 4 ,

—X—Y—R 4 , and

—X—R 5 ;

R 3 is selected from the group consisting of:

—Z-Ar,

—Z-Ar′—Y—R 4 ,

—Z-Ar′—X—Y—R 4 ,

—Z-Ar′—R 5 , and

—Z-Ar′—X—R 5 ;

Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino;

Ar′ is selected from the group consisting of arylene and heteroarylene both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino;

each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more —O— groups;

X′ is C 2-8 alkylene;

each Y is independently selected from the group consisting of:

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene;

each R 4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

each R 5 is independently selected from the group consisting of:

each R 6 is independently selected from the group consisting of ═O and ═S;

each R 7 is independently C 2-7 alkylene;

R 8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R 9 is selected from the group consisting of hydrogen and alkyl;

each R 10 is independently C 3-8 alkylene;

A is selected from the group consisting of —O—, —C(O)—, —S(O) 0-2 —, —CH 2 —, and —N(R 4 )—;

Q is selected from the group consisting of a bond, —C(R 6 )—, —C(R 6 )—C(R 6 )—, —S(O) 2 —, —C(R 6 )—N(R 8 )—W—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, and —C(R 6 )—N(OR 9 )—;

V is selected from the group consisting of —C(R 6 )—, —O—C(R 6 )—, —N(R 8 )—C(R 6 )—, and —S(O) 2 —;

W is selected from the group consisting of a bond, —C(O)—, and —S(O) 2 —; and

a and b are independently integers from 1 to 6 with the proviso that a+b is ≦7; or a pharmaceutically acceptable salt thereof.

2. The compound or salt of claim 1 wherein X′ is —CH 2 —C(CH 3 ) 2 —.

3. The compound or salt of claim 1 wherein R 2 is selected from the group consisting of hydrogen, C 1-4 alkyl, and C 1-4 alkyl-O—C 1-4 alkylenyl.

4. The compound or salt of claim 1 wherein R 4 is selected from the group consisting of alkyl, aryl, and heteroaryl.

5. The compound or salt of claim 1 wherein R 3 is phenyl or pyridyl, either of which can be unsubstituted or can be substituted by one or more substituents selected from the group consisting of halogen, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkylsulfonylamino, arylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, alkylsulfonylaminoalkylenyl, arylsulfonylaminoalkylenyl, alkylcarbonylaminoalkylenyl, and arylcarbonylaminoalkylenyl.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2011
From: COLEY PHARMACEUTICAL GROUP, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 026732/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2007
From: 3M COMPANY; 3M INNOVATIVE PROPERTIES COMPANY
To: COLEY PHARMACEUTICAL GROUP, INC.
Reel/Frame 019965/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2007
From: 3M COMPANY; 3M INNOVATIVE PROPERTIES COMPANY
To: COLEY PHARMACEUTICAL GROUP, INC.
Reel/Frame 019955/0001 →